Nearly half of all leukemia patients waiting for bone marrow transplant experience an unwanted reaction of their immune system which often attacks their skin and liver and in up to 50% of cases the intestines.

‘New molecular mechanism finding could lead to therapies being developed to influence intestinal inflammation after transplants, further increasing patients' chances of survival after a stem cell transplant.’

The group led by Professor Hildner in cooperation with the Department of Medicine 5 and working groups from Frankfurt, Regensburg and Würzburg were also able to demonstrate another connection: T-lymphocytes from the donor which migrate into the intestines release a messenger substance (GM-CSF - granulocyte-macrophage colony-stimulating factor) which triggers the inflammatory reaction in the intestines. When researchers used medication to prevent these specialised T-lymphocytes from developing and functioning, the inflammation in the intestines disappeared. 




Source-Eurekalert